| Autor: |
Yee LK; Department of Medicine and Clinical Pharmacology, Brown University, Rhode Island Hospital, Providence 02903, USA., Chu E, Pan BC, Chu SH, Chen TM, Lipsky MH, Chu MY, Calabresi P |
| Jazyk: |
angličtina |
| Zdroj: |
Pharmacology [Pharmacology] 1998 Feb; Vol. 56 (2), pp. 80-91. |
| DOI: |
10.1159/000028185 |
| Abstrakt: |
At a nontoxic growth inhibitory concentration benzyloxyacyclouridine (BAU), a potent and specific inhibitor of uridine phosphorylase (UrdPase), enhanced 5-fluorouracil (5-FU) cytotoxic activity against human prostate cancer PC-3 and DU-145 cell lines. The BAU/5-FU combination exhibited greater antitumor activity in vivo using PC-3 human xenografts compared to 5-FU alone, with no associated increase in animal host toxicity. The mechanism(s) responsible for the enhanced in vitro and in vivo activity of this combination may involve enhanced formation of the 5-FU nucleotide metabolites FdUMP, FdUTP, and FUTP resulting in enhanced inhibition of thymidylate synthase (TS) and increased incorporation of fluoropyrimidine metabolites into tumoral RNA and DNA. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
